Peroxisome proliferator-activated receptor ä promotes colonic inflammation and tumor growth

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 19, 2014, Pages 7084-7089

  Wang, Dingzhi ^a   Fu, Lingchen ^a   Ning, Wei ^a   Guo, Lixia ^a   Sun, Xiaofei ^b   Dey, Sudhansu K ^b   Chaturvedi, Rupesh ^a   Wilson, Keith T ^a   DuBois, Raymond N ^a,c,d  

^a ARIZONA STATE UNIVERSITY   (United States)

^b CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAYO CLINIC   (United States)

Author keywords

Colorectal cancer; COX 2 PGE2

Indexed keywords

CHEMOKINE; CXCL1 CHEMOKINE; CYCLOOXYGENASE 2; DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 1BETA; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROSTAGLANDIN E2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL LINE; CHRONIC INFLAMMATION; COLON ADENOMA; COLON CARCINOGENESIS; COLON MUCOSA; CONTROLLED STUDY; CYCLOOXYGENASE 2 GENE; CYTOKINE PRODUCTION; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; EPITHELIUM CELL; GENE; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; LEUKOCYTE; MACROPHAGE; MOLECULAR INTERACTION; MOUSE; NONHUMAN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA GENE; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH;

COLORECTAL CANCER; COX-2/PGE2;

ADENOMA; ANIMALS; CELL COMMUNICATION; CELL LINE, TUMOR; COLITIS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE 2; DEXTRAN SULFATE; DIETARY FATS; DINOPROSTONE; EPITHELIAL CELLS; HUMANS; MACROPHAGES; MALE; MICE; MICE, KNOCKOUT; MONOCYTES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84900471198     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1324233111     Document Type: Article

References (44)

1. Ekbom A, Helmick C, Zack M, Adami HO (1990) Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med 323(18):1228-1233.
2. Greten FR, et al. (2004) IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118(3):285-296.
3. Grivennikov S, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15(2):103-113.
4. Wang K, Grivennikov SI, Karin M (2013) Implications of anti-cytokine therapy in co-lorectal cancer and autoimmune diseases. Ann Rheum Dis 72(Suppl 2):ii100-ii103.
5. Ogino S, et al. (2008) Cyclooxygenase-2 expression is an independent predictor of poor prognosis in colon cancer. Clin Cancer Res 14(24):8221-8227.
6. Eberhart CE, et al. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107(4):1183-1188.
7. Sheehan KM, et al. (1999) The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 282(13):1254-1257.
8. Rigas B, Goldman IS, Levine L (1993) Altered eicosanoid levels in human colon cancer. J Lab Clin Med 122(5):518-523.
9. Wang D, Dubois RN (2010) Eicosanoids and cancer. Nat Rev Cancer 10(3):181-193.
10. Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J (1986) Effects of topical 5-ami-nosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 91(4):837-844.
11. Singer II, et al. (1998) Cyclooxygenase 2 is induced in colonic epithelial cells in inflammatory bowel disease. Gastroenterology 115(2):297-306.
12. Schmid A (2011) The role of meat fat in the human diet. Crit Rev Food Sci Nutr 51(1): 50-66.
13. Woutersen RA, Appel MJ, van Garderen-Hoetmer A, Wijnands MV (1999) Dietary fat and carcinogenesis. Mutat Res 443(1-2):111-127.
14. Berger JP, Akiyama TE, Meinke PT (2005) PPARs: Therapeutic targets for metabolic disease. Trends Pharmacol Sci 26(5):244-251.
15. Michalik L, Desvergne B, Wahli W (2004) Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 4(1):61-70.
16. Higashiyama H, Billin AN, Okamoto Y, Kinoshita M, Asano S (2007) Expression profiling of peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray. Histochem Cell Biol 127(5):485-494.
17. Wang D, DuBois RN (2010) Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am 39(3):697-707.
18. Nadra K, et al. (2006) Differentiation of trophoblast giant cells and their metabolic functions are dependent on peroxisome proliferator-activated receptor beta/delta. Mol Cell Biol 26(8):3266-3281.
19. Lee JW, et al. (2007) Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice. Gastroenterology 133(1):108-123.
20. Gupta RA, et al. (2004) Activation of nuclear hormone receptor peroxisome pro-liferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med 10(3):245-247.
21. Wang D, et al. (2004) Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell 6(3):285-295.
22. Wang D, et al. (2006) Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci USA 103(50): 19069-19074.
23. Zuo X, et al. (2009) Targeted genetic disruption of peroxisome proliferator-activated receptor-delta and colonic tumorigenesis. J Natl Cancer Inst 101(10):762-767.
24. Nagy TA, et al. (2011) β-Catenin and p120 mediate PPARδ-dependent proliferation induced by Helicobacter pylori in human and rodent epithelia. Gastroenterology 141(2):553-564.
25. Harman FS, et al. (2004) Peroxisome proliferator-activated receptor-delta attenuates colon carcinogenesis. Nat Med 10(5):481-483.
26. Hollingshead HE, et al. (2007) PPARbeta/delta protects against experimental colitis through a ligand-independent mechanism. Dig Dis Sci 52(11):2912-2919.
27. Wang D, Dubois RN, Richmond A (2009) The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol 9(6):688-696.
28. Khan WI, et al. (2006) Critical role of MCP-1 in the pathogenesis of experimental colitis in the context of immune and enterochromaffin cells. Am J Physiol Gastrointest Liver Physiol 291(5):G803-G811.
29. Andres PG, et al. (2000) Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: Lack of CC che-mokine receptor 5 expression results in a NK1.1+ lymphocyte-associated Th2-type immune response in the intestine. J Immunol 164(12):6303-6312.
30. Tokuyama H, et al. (2005) The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfate-mediated colitis. Int Immunol 17(8):1023-1034.
31. Wang D, Mann JR, DuBois RN (2005) The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology 128(5):1445-1461.
32. Dubois RN, et al. (1998) Cyclooxygenase in biology and disease. FASEB J 12(12): 1063-1073.
33. Glinghammar B, Skogsberg J, Hamsten A, Ehrenborg E (2003) PPARdelta activation induces COX-2 gene expression and cell proliferation in human hepatocellular carcinoma cells. Biochem Biophys Res Commun 308(2):361-368.
34. Pedchenko TV, Gonzalez AL, Wang D, DuBois RN, Massion PP (2008) Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol 39(6):689-696.
35. Di-Poï N, Tan NS, Michalik L, Wahli W, Desvergne B (2002) Antiapoptotic role of PPARbeta in keratinocytes via transcriptional control of the Akt1 signaling pathway. Mol Cell 10(4):721-733.
36. Hoque A, et al. (2005) Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: A potential target for prevention. Carcino-genesis 26(4):785-791.
37. Morteau O, et al. (2000) Impaired mucosal defense to acute colonic injury in mice lacking cyclooxygenase-1 or cyclooxygenase-2. J Clin Invest 105(4):469-478.
38. Kohno H, Suzuki R, Sugie S, Tanaka T (2005) Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 5:46.
39. Jiang GL, et al. (2007) The prevention of colitis by E Prostanoid receptor 4 agonist through enhancement of epithelium survival and regeneration. J Pharmacol Exp Ther 320(1):22-28.
40. Sheibanie AF, et al. (2007) The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23→IL-17 axis. J Immunol 178(12):8138-8147.
41. Mahida YR (2000) The key role of macrophages in the immunopathogenesis of inflammatory bowel disease. Inflamm Bowel Dis 6(1):21-33.
42. Wang D, et al. (2006) CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med 203(4):941-951.
43. Yoshinaga M, et al. (2011) The expression of both peroxisome proliferator-activated receptor delta and cyclooxygenase-2 in tissues is associated with poor prognosis in colorectal cancer patients. Dig Dis Sci 56(4):1194-1200.
44. Dieleman LA, et al. (1998) Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 114(3): 385-391.